Daniel G K Rasmussen1,2, Tine W Hansen3, Bernt J von Scholten3, Signe H Nielsen4,5, Henrik Reinhard3, Hans-Henrik Parving6, Martin Tepel2,7, Morten A Karsdal4, Peter K Jacobsen8, Federica Genovese4, Peter Rossing3,9. 1. Nordic Bioscience, Herlev, Denmark dgr@nordicbio.com. 2. Institute of Molecular Medicine, Cardiovascular and Renal Research, University of Southern Denmark, Odense, Denmark. 3. Steno Diabetes Center Copenhagen, Gentofte, Denmark. 4. Nordic Bioscience, Herlev, Denmark. 5. Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark. 6. Department of Medical Endocrinology, Rigshospitalet, Copenhagen, Denmark. 7. Department of Nephrology, Odense University Hospital, Odense, Denmark. 8. Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 9. Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Abstract
OBJECTIVE: Type 2 diabetes is a common risk factor for the development of chronic kidney disease (CKD). Enhanced de novo collagen type VI (COL VI) formation has been associated with renal fibrosis and CKD. We investigated the hypothesis that PRO-C6, a product specifically generated during COL VI formation, is prognostic for adverse outcomes in patients with type 2 diabetes and microalbuminuria. RESEARCH DESIGN AND METHODS: In a prospective, observational study, we measured PRO-C6 in the serum (S-PRO-C6) and urine (U-PRO-C6) of 198 patients with type 2 diabetes and microalbuminuria without symptoms of coronary artery disease. Patients were followed for a median of 6.5 years, and end points were a composite of cardiovascular events (n = 38), all-cause mortality (n = 26), and reduction of estimated glomerular filtration rate (eGFR) of >30% (disease progression [n = 42]). Cox models were unadjusted and adjusted for the conventional risk factors of sex, age, BMI, systolic blood pressure, LDL cholesterol, smoking, HbA1c, plasma creatinine, and urinary albumin excretion rate. RESULTS: Doubling of S-PRO-C6 increased hazards for cardiovascular events (hazard ratio 3.06 [95% CI 1.31-7.14]), all-cause mortality (6.91 [2.96-16.11]), and disease progression (4.81 [1.92-12.01]). Addition of S-PRO-C6 to a model containing conventional risk factors improved relative integrated discrimination by 22.5% for cardiovascular events (P = 0.02), 76.8% for all-cause mortality (P = 0.002), and 53.3% for disease progression (P = 0.004). U-PRO-C6 was not significantly associated with any of the outcomes. CONCLUSIONS: S-PRO-C6 generated during COL VI formation predicts cardiovascular events, all-cause mortality, and disease progression in patients with type 2 diabetes and microalbuminuria.
OBJECTIVE:Type 2 diabetes is a common risk factor for the development of chronic kidney disease (CKD). Enhanced de novo collagen type VI (COL VI) formation has been associated with renal fibrosis and CKD. We investigated the hypothesis that PRO-C6, a product specifically generated during COL VI formation, is prognostic for adverse outcomes in patients with type 2 diabetes and microalbuminuria. RESEARCH DESIGN AND METHODS: In a prospective, observational study, we measured PRO-C6 in the serum (S-PRO-C6) and urine (U-PRO-C6) of 198 patients with type 2 diabetes and microalbuminuria without symptoms of coronary artery disease. Patients were followed for a median of 6.5 years, and end points were a composite of cardiovascular events (n = 38), all-cause mortality (n = 26), and reduction of estimated glomerular filtration rate (eGFR) of >30% (disease progression [n = 42]). Cox models were unadjusted and adjusted for the conventional risk factors of sex, age, BMI, systolic blood pressure, LDL cholesterol, smoking, HbA1c, plasma creatinine, and urinary albumin excretion rate. RESULTS: Doubling of S-PRO-C6 increased hazards for cardiovascular events (hazard ratio 3.06 [95% CI 1.31-7.14]), all-cause mortality (6.91 [2.96-16.11]), and disease progression (4.81 [1.92-12.01]). Addition of S-PRO-C6 to a model containing conventional risk factors improved relative integrated discrimination by 22.5% for cardiovascular events (P = 0.02), 76.8% for all-cause mortality (P = 0.002), and 53.3% for disease progression (P = 0.004). U-PRO-C6 was not significantly associated with any of the outcomes. CONCLUSIONS:S-PRO-C6 generated during COL VI formation predicts cardiovascular events, all-cause mortality, and disease progression in patients with type 2 diabetes and microalbuminuria.
Authors: Linus Angenendt; Jan-Henrik Mikesch; Dennis Görlich; Alina Busch; Irina Arnhold; Claudia Rudack; Wolfgang Hartmann; Eva Wardelmann; Wolfgang E Berdel; Markus Stenner; Christoph Schliemann; Inga Grünewald Journal: Cell Oncol (Dordr) Date: 2018-06-15 Impact factor: 6.730
Authors: Federica Genovese; Ahmad Akhgar; Sung Sam Lim; Alton B Farris; Monica Battle; Jason Cobb; Dominic Sinibaldi; Morten A Karsdal; Wendy I White Journal: Kidney360 Date: 2021-06-18
Authors: Nadja Sparding; Daniel Guldager Kring Rasmussen; Federica Genovese; Morten Asser Karsdal; Mads Hornum; Bo Feldt-Rasmussen; Rebecca Packington; Nicholas M Selby Journal: Kidney360 Date: 2022-03-03
Authors: Jean Farup; Jesper Just; Frank de Paoli; Lin Lin; Jonas Brorson Jensen; Tine Billeskov; Ines Sanchez Roman; Cagla Cömert; Andreas Buch Møller; Luca Madaro; Elena Groppa; Rikard Göran Fred; Ulla Kampmann; Lars C Gormsen; Steen B Pedersen; Peter Bross; Tinna Stevnsner; Nikolaj Eldrup; Tune H Pers; Fabio M V Rossi; Pier Lorenzo Puri; Niels Jessen Journal: Cell Metab Date: 2021-10-21 Impact factor: 31.373
Authors: Majken Lindholm; Line E Godskesen; Tina Manon-Jensen; Jens Kjeldsen; Aleksander Krag; Morten A Karsdal; Joachim H Mortensen Journal: Sci Rep Date: 2021-07-19 Impact factor: 4.379